United Therapeutics (UTHR) EV to CFO (2009 - 2026)

United Therapeutics has disclosed EV to CFO across 18 years of filings, most recently posting 65.25 for Q2 2026.

• In Q2 2026, EV to CFO rose 25.78% year-over-year to 65.25; the TTM figure through Jun 2026 stood at 12.14 (up 67.44% YoY), while the FY2025 annual figure was 11.75, up 24.24% from the prior year.
• EV to CFO came in at 65.25 for Q2 2026 at United Therapeutics, up from 49.31 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 77.71 in Q4 2022 to a low of 19.78 in Q1 2024.
• Average EV to CFO over 5 years is 42.37, with a median of 42.46 recorded in 2024.
• Year-over-year, EV to CFO tumbled 68.37% in 2022 and soared 115.06% in 2026.
• Over 5 years, EV to CFO stood at 77.71 in 2022, then slumped by 37.24% to 48.77 in 2023, then fell by 24.57% to 36.79 in 2024, then soared by 44.05% to 52.99 in 2025, then increased by 23.13% to 65.25 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 65.25 in Q2 2026, 49.31 in Q1 2026, and 52.99 in Q4 2025.